Key Points
- Martine Rothblatt sold 4,000 shares of United Therapeutics at an average price of $490.70 for a total of $1.9628 million, leaving her with 130 shares — a 96.85% decrease in her ownership.
- United Therapeutics beat earnings with $7.16 EPS (vs. $6.89 estimate) and revenue of $799.5M (up 6.8% YoY), while analysts have raised targets and the consensus price target sits at $505.
- The stock is trading near its 52-week high (opened $493.99, 52-week high $496.73) with a market cap of about $21.27B and a PE of 18.72, and it has 94.08% institutional ownership.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Jan Malcolm sold 50 shares of the firm's stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $482.98, for a total value of $24,149.00. Following the completion of the sale, the director owned 470 shares in the company, valued at approximately $227,000.60. This represents a 9.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $493.99 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $496.73. The stock has a market cap of $21.27 billion, a P/E ratio of 18.72, a P/E/G ratio of 4.85 and a beta of 0.86. The stock has a 50-day simple moving average of $457.81 and a 200-day simple moving average of $374.01.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts' expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm's revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.39 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company's stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. raised its position in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company's stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the 3rd quarter worth $317,617,000. Assetmark Inc. boosted its holdings in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company's stock valued at $205,695,000 after acquiring an additional 197,384 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of United Therapeutics by 0.7% in the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock valued at $192,571,000 after acquiring an additional 4,145 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on UTHR shares. UBS Group upped their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the company a "buy" rating in a report on Thursday, November 6th. Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. Royal Bank Of Canada raised their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a report on Thursday, October 30th. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a research report on Thursday, October 30th. Finally, HC Wainwright raised their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research note on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $505.00.
Get Our Latest Research Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
